Samsung's weight in Kospi hits 9-year low on chip setbacks
The tech giant's common shares accounted for 14.53 percent of the main board's total market capitalization last month, according to the Korea Financial Investment Association. Including preferred shares, the figure stood at 16.17 percent.
The common stock ratio matched its lowest figure since March 2016, while the combined figure was the lowest since a month before that, when it had reached 15.83 percent, data showed.
The market cap ratio reflects the average proportion of Samsung's closing market value against the total market capitalization of all listed stocks on the Kospi, measured daily over a month.
Market watchers attribute the decline in Samsung's market dominance to continued underperformance in its chip division, the device solutions unit. Losses in its foundry and nonmemory operations have dragged down earnings, while the firm's competitiveness in high-bandwidth memory technology has yet to be fully proven.
As a result, when the Kospi jumped 13.86 percent last month, buoyed by institutional and foreign buying, the tech giant's shares rose only 6.41 percent. The tech giant's market cap stood at 353.99 trillion won ($259.8 billion) as of June 30.
While Samsung is scheduled to release its second-quarter earnings guidance on Tuesday, market watchers expect the company to have reached the bottom of its earnings in the second quarter, with performance expected to improve from the third quarter as revenue from HBM increases.
In the second half, Samsung plans to maintain its NAND production cutbacks while focusing on high-value products such as enterprise solid-state drives.
In the high-bandwidth memory segment, the company will accelerate supply discussions for its 12-layer fifth-generation HBM chips -- HBM3E -- with Nvidia, and is also targeting mass production of its sixth-generation HBM -- HBM4 -- later this year.
In the foundry business, Samsung will ramp up its efforts to commercialize its 2-nanometer node for chip production by year-end.
The division that focuses on system-on-a-chip products will also prepare the launch of the in-house Exynos 2500 for the upcoming Galaxy Z Flip 7, with plans to mass-produce the next-generation Exynos 2600 later this year in a bid to narrow operating losses.
'HBM sales to major clients like AMD are expected to rise and losses in the nonmemory segment are likely to narrow,' said Park Yu-ak, an analyst at Kiwoom Securities. 'Stock momentum could strengthen in the third quarter as Samsung begins supplying HBM3E to Nvidia and demonstrates competitive strength in HBM4 technology with new foundry clients.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
11 hours ago
- Korea Herald
Seoul shares soar over 1% on rate-cut hopes
South Korean stocks rose more than 1 percent Wednesday to end a three-day losing streak as hopes for a US rate cut fueled foreign buying. The local currency gained ground against the US dollar. The benchmark Korea Composite Stock Price Index added 34.46 points, or 1.08 percent, to close at 3,224.37. The index had dropped for three straight sessions since Friday. Trade volume was moderate at 316.4 million shares worth 10.2 trillion won ($7.39 billion), with decliners beating gainers 470 to 410. Foreigners bought a net 634 billion won worth of stocks to lead the bullish mode, while institutions and individuals sold a net 80.8 billion won and 660.1 billion won, respectively. Investors were buoyed by better-than-expected US July inflation data, which many believe may have given the Federal Reserve a leeway for a rate cut next month. "The US consumer prices index rose broadly in line with expectations, easing concerns over tariff-led inflation," said Han Ji-young, an analyst from Kiwoom Securities Co. "Still, some investors are worried about uncertainties over the government's tax revision," Han added, referring to Seoul's potential plan to broaden the definition of large shareholders aimed at boosting capital gains tax revenues. Market bellwether Samsung Electronics rose 1.13 percent to 71,900 won, and chipmaking giant SK hynix jumped 3.35 percent to 278,000 won. LG Display surged 22.49 percent to 13,290 won following news reports that US trade authorities have recently imposed a near 15-year import ban on organic light-emitting diode panels produced by China's BOE Technology Group Co. in a complaint filed by Samsung Display. Top carmaker Hyundai Motor advanced 1.41 percent to 216,000 won, and national flag carrier Korean Air gained 5.45 percent to 25,150 won. Major shipyard HD Korea Shipbuilding & Offshore Engineering vaulted 6.6 percent to 379,500 won, and defense behemoth Hanwha Aerospace mounted 3.17 percent to 878,000 won. However, food giant Nongshim fell 1.05 percent to 376,000 won, and leading IT firm Kakao declined 0.31 percent to 63,500 won. The local currency was quoted at 1,381.7 won against the greenback at 3:30 p.m., up 8.2 won from the previous session. (Yonhap)
Korea Herald
18 hours ago
- Korea Herald
HLB appoints Brian Kim as CEO of US subsidary Elevar Therapeutics
Korean biopharmaceutical firm HLB said Wednesday it has appointed Brian Kim, current CEO of HLB Innovation and Verismo Therapeutics, as CEO of its US subsidiary, Elevar Therapeutics. Kim will lead all three companies concurrently. HLB said the leadership change is a strategic move to align with the skills needed at each stage of drug development, particularly as Elevar prepares to enter the commercialization phase and expand global partnerships with big pharma. Kim holds extensive experience in finance, strategic business management and biotechnology, including research in CAR-T cancer treatments and founding multiple biotech firms. A former tenured clinical professor at the University of Pennsylvania School of Dental Medicine, Kim was a founding member of Nasdaq-listed Inovio Pharmaceuticals. He has invested in various businesses, including acquiring a Kospi-listed company and elevating it into the Kospi 200 index. Kim also has invested in and led several biotech ventures in both the US and Korea. 'I feel a deep sense of responsibility taking on this role at such a pivotal moment,' Kim said. 'My focus will be on securing regulatory approval for Elevar's lead liver cancer therapy and ensuring its successful commercialization, while driving sustainable growth for the company.' HLB added that Kim's leadership will help accelerate Elevar's global business expansion and innovation in oncology therapeutics.
Korea Herald
20 hours ago
- Korea Herald
Seoul shares start higher on US gains
South Korean stocks opened higher Wednesday, tracking overnight gains on Wall Street driven by rate cut hopes. The benchmark Korea Composite Stock Price Index rose 25.68 points, or 0.81 percent, to 3,215.59 in the first 15 minutes of trading. US stocks finished higher on the better-than-expected consumer prices report, sparking hopes that the Federal Reserve may cut its key rate at its next meeting in September. The Dow Jones Industrial Average rose 1.1 percent, and the Nasdaq composite advanced 1.39 percent. In Seoul, most shares started in positive territory. Market bellwether Samsung Electronics rose 0.84 percent, and chip giant SK hynix jumped 2.42 percent. Top carmaker Hyundai Motor gained 1.17 percent, and major shipbuilder HD Korea Shipbuilding & Offshore Engineering vaulted 7.02 percent. Samyang Foods, an instant noodle maker well known for its global hit Buldak ramyeon, increased 0.21 percent, and national flag carrier Korean Air climbed 3.14 percent. The local currency was trading at 1,383.95 won against the greenback at 9:15 a.m., up 5.95 won from the previous session. (Yonhap)
